No Data
Express News | J&J: On April 15, FDA Approved Stelara for Treatment of Patients Two Years and Older With Moderately to Severely Active Crohn’s Disease
S&P 500's Best‐Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
Option Care Health Downgraded at BofA on Guidance Cut
Medcura Appoints Medical Device Industry Veteran Gary P. Fischetti to Board of Directors
Fundraising Update: Senator Pete Ricketts Just Disclosed $157.7K of New Fundraising
Express News | Johnson & Johnson Statement On Investigational Programs In Large B-cell Lymphoma; To Discontinue CD20 And CD19-CD20 CAR-T Programs; To Continue Support For Patients In Discontinued Investigational CD20 Mono CAR-T Cell Therapy And CD19-CD20 Bi-CAR-T...
Wall Street Raider : Downwards trend at the moment.
71732910 : I was wondering the same thing. The Healthcare industry has been going down the past few sessions.
Garrisbear : Price way over inflated. Just like oil, a good stock to short over the coming month.
75798542 Garrisbear : Rather than saying it's overvalued, it's more about the market improving and people withdrawing money from Johnson & Johnson to buy tech stocks instead
74064212 75798542 : Completely possible